Network pharmacology-based strategy for antitumor drug discovery
XIAO Zhi-yong;ZHOU Wen-xia;ZHANG Yong-xiang;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;

..............page:1-6

juan shou yu

..............page:3

Biological function and inhibitors of mTOR:research advances
CAO Shuang;ZHONG Wu;National Engineering Research Center for the Strategic Drug;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;

..............page:6-20+4

ben kan lun wen ru xuan f5000 zhong guo jing pin ke ji qi kan ding jian xue shu lun wen

..............page:20

Fragment-based drug design:discovery and development of HSP90 inhibitor
HE Xiao-yang;WANG Sheng-qi;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:21-29+4

guo ji yao xue yan jiu za zhi yi bei 10 zhong guo ji zhong yao shu ju ku shou lu

..............page:29

New target for cancer therapy:epigenetical histone lysine specific demethylase 1
ZHENG Yi-chao;MA Jin-lian;WANG Zhi-ru;LI Jin-feng;ZHAO Wen;LIU Hong-min;School of Pharmacecctical Sciences;New Drug Research & Development Center;Zhengzhou Unirversity;

..............page:30-36+4

Cyclin dependent kinase and structure-activity relationship with their inhibitors:research advances
LIU Wen-hu;CHANG Jin-xia;WANG Shi-bao;Department of Pharmacy;North Sichuan Medical College;Department of Microbiology and Immunology;North Sichuan Medical College;Department of Pharmacology;Hanzhong Vocation and Technology College;

..............page:37-44+56

Development of antibody-drug conjugates as targeted cancer therapeutics
YANG Yue-mei;ZHANG Bo-yan;LI Yan;SHEN Bei-fen;Department of Molecular Immunology;Institute of Basic Medical Sciences;Academy of Military Medical Sciences;Beijing Mabworks Biotech Co.;Ltd.;

..............page:45-50+4

Pharmacogenomics on anti-cancer drugs:research advances
LIU Jing-tao;JIAO Yuan-yuan;ZHANG Yan-hua;Ministry of Education;Key laboratory of Carcinogenesis and Translational Research;Pharmacy Department;Peking University Cancer Hospital & Institute;

..............page:51-56+4

Cancer immunotherapy:research advances
WEI Xiao-li;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;

..............page:57-62+4

Inflammation:a driver for tumor development
WANG Yi;LI Yan;SHEN Bei-fen;CHEN Guo-jiang;Institute of Basic Medical Sciences;Academy of Military Medical Sciences;

..............page:63-67+74+4

Nano-formulations for tumor targeting:research advances
WEI Li-Sha;JI Yan-xia;KANG Zhen-qiao;ZHENG Ai-ping;Department of Pharmaceutics;Institute of Pharmacology and Toxicology;Academy of Military Medical Sciences;Handan Central Hospital;

..............page:68-74+4

Effects of efflux transporters on disposition of tyrosine kinase inhibitors
LIN Li-shan;CHEN Xiao-yan;ZHONG Da-fang;Shanghai Institute of Materia Medica;Chinese Academy of Sciences;

..............page:75-82+4

guo ji yao xue yan jiu za zhi 2013 nian du te yao shen gao zhuan jia ming dan

..............page:82

Tissue engineering tumor based on three-dimensional culture:research advances
QIAO Xin;WANG Yan;Department of Advanced Interdisciplinary Studies;Institute of Basic Medical Sciences;Academy of Military Medical Sciences;

..............page:83-89+4

Synthesis and in vitro cytotoxicity of polyethylene glycol-epothilone B conjugates
ZHANG Hai-yan;WANG Kun;LU Yu-xin;CHENG Xiao-chen;ZHANG Qin-lin;School of Pharmacy;Central South University;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:90-93+4

hui rui xuan bu tuo fa ti ni kou fu zhi liao yin xie bing 2 xiang qi lin chuang shi yan qu de cheng gong
zhao wen li ;

..............page:93

Target molecules and related drugs stimulating cholesterol efflux:research advances
ZHANG Xue;WU Chong-ming;GUO Peng;Research Center on Life Sciences and Environment Sciences;Harbin University of Commerce;Pharmacology and Toxicology Research Center;Institute of Medicinal Plant Development;Chinese Academy ofMedical Sciences;Peking Union Medical College;

..............page:94-97+113

Clinical application of pramipexole dihydrochloride extended release tablets
LIU Yu-li;Pharmacy Department;Inner Mongolia Medical University People’s Hospital;

..............page:98-101

Inhibited effect of phosphorothioate antisense oligonucleotides prop5 on entry of influenza virus into cells
LI Kang;QI Xiang-yun;LI Qing-ping;XA Yan-ping;YANG Jing;WANG Sheng-qi;College of Life Science and Bio-engineering;Beijing University of Technology;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:102-107+117+4

Pharmacokinetic study of paeoniflorin and albiflorin in Si-Wu decoction in rats by LC-MS /MS
HUANG Kai-fu;WANG Xue-mei;MENG Zhi-yun;GAO Yue;LI Jian;GAN Hui;WU Zhuo-na;ZHU Xiao-xia;GU Ruo-lan;DOU Gui-fang;Institute of Transfusion Medicine;Academy of Military Medical Sciences;Peking University First Hospital;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:108-113

Content determination of clonidine hydrochloride in Zhenju Jiangya tablets by solid phase extraction-HPLC
QIAN Guo-hua;XU Ling-ling;ZHANG Meng-ling;JING Ying-chun;Shanghai Lei Yun Shang Pharmaceutical co.;LTD;Shanghai University of TCM;

..............page:114-117

Simultaneous quantification of antisense oligonucleotides and its metabolite in biological samples by a nucleic acid hybridization combined enzyme-linked bridging method based on suspension array technology
LIU Qian;SUN Yun-juan;FU Jie;SONG Hai-feng;School of Pharmacy;China Central South University;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:118-124

Overviews and analysis of the U.S.FDA’s new approvals in the 2013 second half year
TANG Zhong-ming;Institute of Radiation Medicine;Academy of Military Medical Sciences;

..............page:125-130

xin yao yan jiu yu kai fa
zhao wen li ;

..............page:131

guo ji yao xue yan jiu za zhi gao yue

..............page:132-134

jun shi yi xue bo wu guan cang pin zheng ji qi shi

..............page:135